Both RI-DR and ODx RS were similarly effective in predicting recurrence-free survival (RFS) in patients with early-stage breast cancer.76 However, the existing literature lacks large-scale, head-to-head comparisons of multigene assays, making it challenging to determine the most effective approach for tailoring adjuvant systemic therapy in early-stage hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer. Here, ERBB2 is linked to breast cancer.